Shukla Sanjay 4

What Happened Sanjay Shukla, President, CEO and a director of aTYR PHARMA INC (ATYR), had 10,375 restricted stock units (RSUs) vest on Feb 3, 2026 and converted them into 10,375 common shares. Following the vesting, he sold 3,745 shares in an open-market transaction on Feb 4, 2026 at $0.98 per share for proceeds of $3,655 to satisfy tax withholding obligations.

Key Details

• Transaction dates: RSU vesting/conversion recorded 2026-02-03; open-market sale 2026-02-04.
• Shares acquired: 10,375 (conversion of vested RSUs). Acquisition price reported as $0.00 (typical for RSU vesting).
• Shares sold: 3,745 at $0.98 each; total proceeds $3,655.
• Reason for sale: Footnote states sale was to satisfy tax withholding on the partial vesting of RSUs.
• RSU terms: These RSUs were granted on Feb 3, 2022, convert one-for-one to common stock, and vest in four equal annual installments beginning Feb 3, 2023 (fully vested Feb 3, 2026). They include accelerated vesting upon a change of control in certain circumstances.
• Shares owned after transaction: Aggregate holdings not specified in the Form 4 filing.
• Filing timeliness: Form filed on 2026-02-04 for a 2026-02-03 transaction — appears timely.

Context This was a standard RSU vesting event (an award converting to common stock) with a small portion sold immediately to cover taxes — a routine, non-speculative administrative sale. The conversion of RSUs is often reported as a derivative exercise/ conversion with $0 consideration because the award vests into shares rather than being purchased.